Robbins LLP said a securities class action has been filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. securities between Aug. 4, 2025, and July 29, 2026. The complaint alleges that Hims shared consumers' protected health information with third-party advertising platforms, including Meta Platforms and Snap, and charged consumers for prescriptions shortly after intake forms were submitted despite describing access to consultation with a medical provider. The allegations followed the Federal Trade Commission's announcement on July 29, 2026, that it had sued Hims over alleged privacy, billing and cancellation practices. Hims shares fell $4.32, or 14.73%, to close at $25.00 that day. Investors with significant losses are urged to contact Robbins LLP before the Nov. 2, 2026, lead plaintiff deadline. Participation is offered on a contingency fee basis, and serving as lead plaintiff is not required to share in any potential recovery.